Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping.

Area of Science:

• Proteomics
• Oncology
• Biochemistry

Background:

• The role of extracellular vesicles (EVs) proteome in diffuse large B-cell lymphoma (DLBCL) pathology is largely unexplored.
• DLBCL comprises distinct molecular subtypes, including germinal center B cell (GCB) and activated B cell (ABC) subtypes, with differing prognoses.

Purpose of the Study:

• To investigate the potential of extracellular vesicle (EV) proteome for subclassification and diagnosis of DLBCL subtypes.
• To identify differentially expressed proteins in EVs and whole cells between GCB and ABC DLBCL subtypes.
• To explore potential therapeutic targets based on proteomic differences.

Main Methods:

• State-of-the-art mass spectrometry was used to analyze whole-cell and secreted EV proteomes from GCB and ABC DLBCL cell lines.
• Proteomic data underwent quality control and comparative analysis to identify differentially expressed proteins (DEPs).
• KEGG and Gene Ontology (GO) enrichment analyses were performed on DEPs to identify enriched biological pathways.

Main Results:

• Both whole-cell and EV proteomes demonstrated the capacity to differentiate between ABC and GCB DLBCL subtypes in preclinical models.
• A significant number of differentially expressed proteins were identified in both whole-cell (288/1115) and EV (228/608) proteomes between subtypes.
• Functional analysis revealed enrichment of immune response, cellular signaling, and intracellular trafficking pathways in DEPs from EVs.

Conclusions:

• Extracellular vesicles (EVs) proteome holds significant potential as a tool for DLBCL patient diagnosis, follow-up, and disease monitoring.
• The study identified novel potential drug targets for aggressive DLBCL, suggesting opportunities for combinatorial therapies.
• Proteomic profiling of EVs provides valuable insights into DLBCL pathobiology and offers avenues for therapeutic development.